AI-biotech sovereignty will define India’s future

If the 20th c. was defined by energy security, and the early 21st c. by digital sovereignty, the coming decades will be shaped by biotech sovereignty embedded in AI. Nations that command convergence of biology and AI will define the future of healthcare, food security, biomanufacturing and biosecurity. For India, this isn't merely an opportunity but a strategic imperative.

Living systems are the original intelligent machines. Cells sense, compute and respond through intricate signalling networks, gene regulation circuits, and immune memory. These systems operate within inbuilt biological guard rails, which focus on feedback loops and control mechanisms that maintain homeostasis, or health equilibrium. Disease arises when these guard rails fail.

AI, by contrast, learns from data to optimise decisions at machine scale. The true inflection point lies at their intersection: AI-powered biology. From protein structure prediction and generative drug design to digital twins of cells and organs, AI is compressing discovery timelines and reducing development risk. The next frontier is even more profound: reprogramming of cells themselves to restore biological balance.


We are moving from static, one-size-fits-all drugs to programmable biology. AI-native platforms are enabling:

Cancer therapies that reprogramme immune cells (CAR-T, TCR-T, NK cells) to recognise and eliminate tumours.

Autoimmune disease interventions that recalibrate immune tolerance rather than suppress immunity.

Longevity and health span strategies that modulate senescence, metabolic pathways and cellular repair mechanisms to delay biological ageing and restore tissue resilience.

These approaches seek not to overpower biology but to reinforce its inbuilt guard rails, which focus on repair, feedback control and immune surveillance. AI can map these regulatory circuits at scale, enabling targeted interventions that preserve homeostasis. This represents a paradigm shift from managing disease to reengineering biological systems to sustain health.

India's future health security will depend on who controls the code of life and intelligence. If foundational AI models for drug discovery, genomics, cellular engineering and clinical decision-making are owned offshore, India risks strategic dependence in human health.

Biotech sovereignty embedded in AI must mean sovereign control over trusted biological data, indigenous AI models, compute infra and translational platforms, from discovery and development to manufacturing and delivery. This is essential not only for economic competitiveness but also for preparedness against pandemics, antimicrobial resistance and emerging bio-threats.

India must evolve from being the 'pharmacy of the world' to becoming the 'biotech platform of the world', offering AI-native discovery engines, programmable therapy platforms and scalable biomanufacturing as global public goods. This requires embedding AI across the biotech value chain:

Discovery Foundation models for proteins, RNA, cellular circuits and systems biology.

Development In-silico trials, digital twins and AI-driven trial design to derisk pipelines.

Manufacturing Smart biomanufacturing using AI for yield optimisation and quality-by-design.

Regulation Science-first, tech-enabled regulatory pathways integrating real-world evidence and AI validation.

Delivery AI-powered pharmacovigilance, personalised medicine and population-scale health optimisation.

This transformation demands a triple helix of government, academia and industry:

GoI must invest in sovereign AI-bio infra, trusted data architectures, national compute, regulatory sandboxes, and mission-mode programmes in cell and gene therapy, immuno-oncology, and longevity science.

Academia must mainstream computational biology, neuro-symbolic AI and AI-first life sciences education to build a new cadre of translational scientists.

Industry must co-create shared platforms, translational pipelines and globally benchmarked biomanufacturing clusters that convert science into scale.

Capital markets must evolve to back long-cycle, high-risk biotech. Deep science needs patient capital. But societal and economic returns are exponential. India must build ethical, transparent, energy-efficient and bias-aware AI for biology - globally interoperable, yet grounded in public interest. By embedding equity, affordability and access into AI-driven biotech, it can offer a model that unites technological leadership with social purpose.

The ability to reprogramme cells - to fight cancer, correct immune dysfunction and extend healthy longevity while preserving the body's natural homeostatic guard rails - will determine who leads the next era of medicine. Those who master the language of life, augmented by the language of machines, will shape the future of humanity.

The writer is founder-chairperson, Biocon Group